Sharing, samples, and generics: an antitrust framework.

Area of Science:

• Pharmaceutical Law and Policy
• Antitrust Law
• Drug Pricing and Access

Background:

• Rising drug prices are limiting consumer access to essential and life-saving medications.
• Brand pharmaceutical firms are increasingly using Risk Evaluation and Mitigation Strategies (REMS) to prevent generic drug market entry.
• Existing regulations like the Hatch-Waxman Act aim to promote generic competition, but their effectiveness is hampered by sample access issues.

Purpose of the Study:

• To analyze how brand firms exploit REMS to block generic competition through sample denial.
• To demonstrate the critical role of drug samples in the regulatory framework for generic drug approval.
• To argue for antitrust intervention to ensure generic access to samples and promote market competition.

Main Methods:

• Analysis of brand firms' justifications for sample denial, including safety and product liability concerns.
• Examination of the regulatory landscape, including the FDA's role and legislative frameworks (Hatch-Waxman Act).
• Application of antitrust legal principles, specifically the 'no economic sense' test, to brand firms' conduct.

Main Results:

• Over 100 generic firms report inability to access necessary samples, costing the market over $5 billion annually.
• Brand firms' justifications for sample denial are rebutted, showing the conduct lacks legitimate business rationale beyond harming competitors.
• The practice of denying samples constitutes a form of monopolization, distinct from other scrutinized antitrust behaviors like 'pay for delay'.

Conclusions:

• The denial of drug samples by brand firms is an anticompetitive practice that warrants antitrust scrutiny.
• Antitrust law can effectively address this issue, ensuring generic access to samples and upholding the pharmaceutical regulatory regime.
• Given the failures of legislative and regulatory bodies, antitrust action is crucial for ensuring fair competition and affordable medicine.